MXC: $0.044
Who

An EU pharmaceutical licensed company, MGC Pharmaceuticals Ltd (ASX: MXC),(MGCLF: OTC US)  is driven by the goal to be a global innovator in Phytocannabinoid-based medicine within the biopharmaceutical industry. With many years of real-world, technical and professional experience, MGC Pharma’s founders are all celebrated trailblazers in the Phytocannabinoid industry. MGC Pharma’s main objective is to create and supply superb Cannabinoid based pharmaceutical products for medical markets in North America, Europe, and Australasia.

Read More Read Edison Research On MGC
What

Endlessly producing value for investors with high yield cultivation, tactical joint ventures, and over 40 years’ collective experience, MGC Pharmaceuticals is a leader in the Medical Cannabis industry. MGC Pharma operates under high standards of QA and QC to diverse sections of the Medical Cannabis industry, permitting us to meet and surpass Good Manufacturing Practice (GMP) and GACP protocols, all over the world.

Read More
Where

Understanding that we work in an evolving industry which resonates worldwide, MGC Pharmaceuticals places high importance on global activities and supply chain. Unified supply and ability to function dynamically are essential. It permits our IP and experience to enable entry into new markets, helps with the growth of innovation investigation and research institutions (from the government to commercial to educational) and guarantees our products will seamlessly and reliably reach patients and customers, with the strictest QC and QA.

Read More
Why

We’re devoted to providing you with the latest company information. This comprises of ASX announcements, financial reports, and other significant updates. You can also access FAQs and see the latest share price information here. MGC Pharmaceuticals trades on the Australian Securities Exchange (ASX) under the ticker code MXC.

Read More
Why Invest
Latest News
27/12/18MGC receives first cannabis epilepsy drug in Australia 26/12/18First CannEpilTM Product arrives in Australia 19/12/18MGC Pharmaceuticals’ commences trading in the US on the OTCQB Venture Market 3/12/18MGC Derma Sale Update – Formal Sale Documents Finalised For Settlement In Slovenian Court
Read More News
Why Phytocannabinoid-based medicines
Publications

Download our publications on Medicinal Cannabis in Australia, Science, Regulation and the industry as a whole. Developed in partnership with prestigious universities, academia and pioneers in the industry, our publications set out the key challenges, risks and opportunities associated with establishing a national Medicinal Cannabis scheme in Australia.

10/8/16Clinical Evidence for Medicinal Cannabis Report 21/3/16Medicinal Cannabis in Australia, Science, Regulation & Industry
Read More Publications
Latest MGC Annual Report
Investor Information

Sign up to MGC Pharma’s Investor Information to receive the latest news, updates, announcements and investor presentations, straight to your inbox.


MGC Pharmaceuticals partners and collaborates with academia, worldwide prominent universities and companies all over the world to conduct extensive research and develop the highest quality products for our patients.

Research and Educational Partners

Distribution Partners

Clients

View all our partners
ASX: MXC
$0.044
Sunday, 20 January 2019
Latest Announcements
18/1/19December Quarterly Activity and Cashflow Report 24/12/18First CannEpil Product arrives in Australia 19/12/18MXC commences trading on the US OTCQB Venture Market 5/12/18Release of Restricted Securities 3/12/18MGC Derma - CannaGlobal Transaction Update 22/11/18Chairman's Address - 2018 AGM 22/11/18Results of Annual General Meeting
Subscribe for news

Australia
Pharma Corporate & Financial Headquarters
Slovenia
Pharma European Operational Headquarters
Malta
Czech Republic
Botanical Research and Development Project
UK
European Corporate Headquarters
Israel
Pharma Scientific Board
Who
What
Where
Why